Is there an increased risk of severe COVID-19 among patients with systemic lupus erythematosus treated with anifrolumab?

After three anifrolumab infusions, she developed cough, sore throat, headache, muscle pain, and a COVID-19 was confirmed by PCR and serological test (2 months later). After three infusions of anifrolumab, she developed cough, sore throat, and headache and a COVID-19 was diagnosed using Polymerase Chain reaction (PCR). [Extracted from the article]